Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 5/2020

28.05.2020 | Review Article

Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences

verfasst von: Brandon E. Cohen, Prashiela Manga, Krysta Lin, Nada Elbuluk

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

There has been a significant increase in the number and efficacy of therapies for advanced melanoma. Immunotherapies, such as anti-cytotoxic T-lymphocyte antigen-4 and programmed cell death-1 inhibitors, have improved the prognosis for patients with advanced melanoma. While spontaneous melanoma-associated vitiligo is a known phenomenon, the occurrence of melanoma-associated vitiligo following melanoma therapy is now recognized to associate with favorable outcomes.

Objective

The objective of this article is to provide a comprehensive literature review of melanoma-associated vitiligo and explore the insights these findings provide about the pathobiology of vitiligo and mechanisms underlying melanoma therapies.

Methods

PubMed and Science Direct databases were searched for studies pertaining to melanoma-associated vitiligo. The 36 studies reviewed included meta-analyses (n = 2), prospective cohort studies (n = 4), prospective observational studies (n = 3), retrospective studies (n = 12), case series (n = 2), and case reports (n = 13).

Results

The basic mechanisms underlying melanoma-associated vitiligo and vitiligo may be shared. Characterization of these mechanisms will identify new biomarkers and therapeutic targets for both melanoma and vitiligo.

Conclusions

Co-opting the immune system to target tumor antigens highlights the potential overlap between anti-tumor immunity and autoimmunity. The development of vitiligo-like depigmentation in association with immunotherapy for melanoma may provide insights into both the immune response against melanoma as well as the pathogenesis of vitiligo.
Literatur
1.
Teulings HE, Willemsen KJ, Glykofridis I, Krebbers G, Komen L, Kroon MW, et al. The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo. Pigment Cell Melanoma Res. 2014;27(6):1086–96.PubMed
2.
Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol. 2006;126(12):2658–63.PubMed
3.
Merimsky O, Shoenfeld Y, Baharav E, Altomonte M, Chaitchik S, Maio M, et al. Melanoma-associated hypopigmentation: where are the antibodies? Am J Clin Oncol. 1996;19(6):613–8.PubMed
4.
Failla CM, Carbone ML, Fortes C, Pagnanelli G, D'Atri S. Melanoma and vitiligo: in good company. Int J Mol Sci. 2019;20(22):5731.PubMedCentral
5.
Fishman P, Azizi E, Shoenfeld Y, Sredni B, Yecheskel G, Ferrone S, et al. Vitiligo autoantibodies are effective against melanoma. Cancer. 1993;72(8):2365–9.PubMed
6.
Daneshpazhooh M, Shokoohi A, Dadban A, Raafat J. The course of melanoma-associated vitiligo: report of a case. Melanoma Res. 2006;16(4):371–3.PubMed
7.
Quaglino P, Marenco F, Osella-Abate S, Cappello N, Ortoncelli M, Salomone B, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol. 2010;21(2):409–14.PubMed
8.
Yang M, Chang D. Vitiligo after immune checkpoint inhibitor therapy in a woman with metastatic melanoma. J Cancer Res Pract. 2018;5:161–4.
9.
Lommerts JE, Teulings HE, Ezzedine K, van Geel N, Hartmann A, Speeckaert R, et al. Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field. J Am Acad Dermatol. 2016;75(6):1198–204.PubMed
10.
Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773–81.PubMed
11.
Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol. 1996;19(1):81–4.PubMed
12.
Gathings R, Lewallen R, Yosipovitch G. Immunotherapy-induced leukoderma from treatment of melanoma with IL-2: a case report and a review of the literature. Acta Derm Venereol. 2015;95(2):197–200.PubMed
13.
Khan R, Gupta S, Sharma A. Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-beta) in patients with vitiligo. J Am Acad Dermatol. 2012;66(3):510–1.PubMed
14.
Shi YL, Li K, Hamzavi I, Lim HW, Zhou L, Mi QS. Elevated circulating soluble interleukin-2 receptor in patients with non-segmental vitiligo in North American. J Dermatol Sci. 2013;71(3):212–4.PubMed
15.
Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763–71.PubMed
16.
Iglesias P, Ribero S, Barreiro A, Podlipnik S, Carrera C, Malvehy J, et al. Induced vitiligo due to talimogene laherparepvec injection for metastatic melanoma associated with long-term complete response. Acta Derm Venereol. 2019;99(2):232–3.PubMed
17.
Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886–94.PubMed
18.
de Golian E, Kwong BY, Swetter SM, Pugliese SB. Cutaneous complications of targeted melanoma therapy. Curr Treat Options Oncol. 2016;17(11):57.PubMed
19.
Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13(22 Pt 1):6681–8.PubMedPubMedCentral
20.
Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100(14):8372–7.PubMedPubMedCentral
21.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.PubMed
22.
Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12–25.PubMedPubMedCentral
23.
Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74(3):455–61.e1.PubMed
24.
Wolner ZJ, Marghoob AA, Pulitzer MP, Postow MA, Marchetti MA. A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. Br J Dermatol. 2018;178(1):265–9.PubMed
25.
Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45–51.PubMed
26.
Larsabal M, Marti A, Jacquemin C, Rambert J, Thiolat D, Dousset L, et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol. 2017;76(5):863–70.PubMed
27.
Nakamura Y, Tanaka R, Asami Y, Teramoto Y, Imamura T, Sato S, et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study. J Dermatol. 2017;44(2):117–22.PubMed
28.
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.PubMed
29.
Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, et al. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol. 2019;145(2):511–21.PubMed
30.
Nardin C, Jeand'heur A, Bouiller K, Valnet-Rabier MB, Dresco F, Castagna J, et al. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients. J Am Acad Dermatol. 2020;82(3):770–2.PubMed
31.
Hwang SJE, Park JJW, Wakade D, Chou S, Byth K, Fernandez-Penas P. Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma. Melanoma Res. 2019;29(2):172–7.PubMed
32.
Quach HT, Dewan AK, Davis EJ, Ancell KK, Fan R, Ye F, et al. Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma. JAMA Oncol. 2019;5(6):906–8.PubMedPubMedCentral
33.
Babai S, Voisin AL, Bertin C, Gouverneur A, Le-Louet H. Occurrences and outcomes of immune checkpoint inhibitors-induced vitiligo in cancer patients: a retrospective cohort study. Drug Saf. 2020;43(2):111–7.PubMed
34.
Nardin C, Pelletier F, Puzenat E, Aubin F. Vitiligo repigmentation with melanoma progression during pembrolizumab treatment. Acta Derm Venereol. 2019;99(10):913–4.PubMed
35.
Plaquevent M, Greliak A, Pinard C, Duval-Modeste AB, Joly P. Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy. Melanoma Res. 2019;29(3):311–2.PubMed
36.
Schwager Z, Laird ME, Latkowski JA. Regression of pigmented lesions in a patient with metastatic melanoma treated with immunotherapy. JAAD Case Rep. 2018;4(5):421–3.PubMedPubMedCentral
37.
Mihailovic N, Dyballa J, Herz S, Fluck M, Alnawaiseh M, Merte RL, et al. Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma [in German]. Ophthalmologe. 2020;117(5):467–71.PubMed
38.
Obata S, Saishin Y, Teramura K, Ohji M. Vogt-Koyanagi-Harada disease-like uveitis during nivolumab (anti-PD-1 antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol. 2019;10(1):67–74.PubMedPubMedCentral
39.
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345–61.PubMed
40.
Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206–12.PubMedPubMedCentral
41.
Billon E, Walz J, Brunelle S, Thomassin J, Salem N, Guerin M, et al. Vitiligo adverse event observed in a patient with durable complete response after nivolumab for metastatic renal cell carcinoma. Front Oncol. 2019;9:1033.PubMedPubMedCentral
42.
Liu RC, Consuegra G, Chou S, Fernandez PP. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. Clin Exp Dermatol. 2019;44(6):643–6.PubMed
43.
Yin ES, Totonchy MB, Leventhal JS. Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: a novel finding. JAAD Case Rep. 2017;3(2):90–2.PubMedPubMedCentral
44.
Kosche C, Mohindra N, Choi JN. Vitiligo in a patient undergoing nivolumab treatment for non-small cell lung cancer. JAAD Case Rep. 2018;4(10):1042–4.PubMedPubMedCentral
45.
Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer. 2017;123(S11):2143–53.PubMed
46.
Lo JA, Fisher DE, Flaherty KT. Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncol. 2015;1(9):1340–1.PubMedPubMedCentral
47.
Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M, et al. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol. 2001;117(6):1464–70.PubMed
48.
Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med. 2000;192(11):1637–44.PubMedPubMedCentral
49.
Byrne KT, Turk MJ. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget. 2011;2(9):684–94.PubMedPubMedCentral
50.
Okamoto T, Irie RF, Fujii S, Huang SK, Nizze AJ, Morton DL, et al. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol. 1998;111(6):1034–9.PubMed
51.
Edmondson LA, Smith LV, Mallik A. Nivolumab-induced vitiligo in a metastatic melanoma patient: a case report. J Oncol Pharm Pract. 2017;23(8):629–34.PubMed
52.
Ramondetta A, Ribero S, Conti L, Fava P, Marra E, Broganelli P, et al. Clinical and pathological relevance of drug-induced vitiligo in patients treated for metastatic melanoma with anti-PD1 or BRAF/MEK inhibitors. Acta Derm Venereol. 2020;100(1):adv00001.
53.
54.
Arowojolu OA, Orlow SJ, Elbuluk N, Manga P. The nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant response promotes melanocyte viability and reduces toxicity of the vitiligo-inducing phenol monobenzone. Exp Dermatol. 2017;26(7):637–44.PubMedPubMedCentral
55.
Jian Z, Li K, Song P, Zhu G, Zhu L, Cui T, et al. Impaired activation of the Nrf2-ARE signaling pathway undermines H2O2-induced oxidative stress response: a possible mechanism for melanocyte degeneration in vitiligo. J Invest Dermatol. 2014;134(8):2221–30.PubMed
56.
Toosi S, Orlow SJ, Manga P. Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol. 2012;132(11):2601–9.PubMedPubMedCentral
57.
58.
Taieb A, Picardo M. Clinical practice: vitiligo. N Engl J Med. 2009;360(2):160–9.PubMed
59.
Hartmann A, Bedenk C, Keikavoussi P, Becker JC, Hamm H, Brocker EB. Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J Dtsch Dermatol Ges. 2008;6(12):1053–9.PubMed
60.
Fukuda K, Harris JE. Vitiligo-like depigmentation in patients receiving programmed cell death-1 inhibitor reflects active vitiligo. J Am Acad Dermatol. 2018;78(1):e15–e1616.PubMed
61.
Nakashima C, Ishida Y, Nakagawa K, Irie H, Hirata M, Kataoka T, et al. Identification of CD49a+ CD8+ resident memory T cells in vitiligo-like lesions associated with nivolumab treatment for melanoma. J Eur Acad Dermatol Venereol. 2020;34(2):e79–82.PubMed
62.
Spritz RA. The genetics of generalized vitiligo: autoimmune pathways and an inverse relationship with malignant melanoma. Genome Med. 2010;2(10):78.PubMedPubMedCentral
Metadaten
Titel
Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences
verfasst von
Brandon E. Cohen
Prashiela Manga
Krysta Lin
Nada Elbuluk
Publikationsdatum
28.05.2020
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 5/2020
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-020-00524-0

Weitere Artikel der Ausgabe 5/2020

American Journal of Clinical Dermatology 5/2020 Zur Ausgabe

Review Article

New and Emerging Targeted Therapies for Vascular Malformations

Review Article

Efficacy of Nonprescription Moisturizers for Atopic Dermatitis: An Updated Review of Clinical Evidence

Original Research Article

Acne Keloidalis Nuchae and the Metabolic Syndrome: A Population-Based Study

Leading Article

Progress to Date in Advancing Stratified Medicine in Psoriasis

Review Article

Cutaneous Manifestations of COVID-19: An Evidence-Based Review

Review Article

Bedside Diagnostics for Infections: A Guide for Dermatologists

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise